Accelr8 Announces New Management
27 Juin 2012 - 5:16PM
Business Wire
Accelr8 Technology Corporation (NYSE MKT: AXK) today
announced the appointment of Lawrence Mehren as President and Chief
Executive Officer and a member of the Board of Directors.
Most recently, Mr. Mehren was Head of Global Business of Ventana
Medical Systems and Roche Tissue Diagnostics, managing its four
business units, as well as Spring Biosciences, and mtm
laboratories. From 2007 until 2010 he held various global
leadership positions with Ventana including Senior Vice President,
Emerging Businesses, and Chief Financial Officer. Previously, he
was Managing Director, Partner and head of P&M Corporate
Finance’s life sciences practice. Prior to his tenure at P&M,
Mr. Mehren worked in management positions with Gale Group, a
division of The Thomson Corporation, as well as Merrill Lynch. Mr.
Mehren holds a B.A. from the University of Arizona and an M.B.A.
from Northwestern University’s Kellogg Graduate School of
Management.
“We are fortunate to have someone of Larry Mehren’s caliber and
experience to lead Accelr8” said John Patience, Chairman of the
Board. “Larry’s vision and proven track record of execution in the
global diagnostics industry will allow us to fully realize the
potential of Accelr8.”
“I am excited to be joining Accelr8 at such a pivotal time,”
said Mehren. “The company has created a unique solution to a
tremendous unmet need. I look forward to advancing the development
and commercialization of this transformational technology.”
About Accelr8
Accelr8 Technology Corporation (www.accelr8.com) is a developer
of innovative materials and instrumentation for advanced
applications in medical instrumentation, basic research, drug
discovery, and bio-detection. Accelr8 is developing a rapid
analytical platform for infectious pathogens, the BACcel™ system,
based on its innovative assay processing and detection
technologies. In addition, Accelr8 licenses certain of its
proprietary technology for use in applications outside of Accelr8’s
own products.
Certain statements in this news release may be “forward-looking
statements” within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. Statements regarding future prospects and
developments are based upon current expectations and involve
certain risks and uncertainties that could cause actual results and
developments to differ materially from the forward-looking
statement, including those detailed in the company's filings with
the Securities and Exchange Commission. Accelr8 does not undertake
an obligation to publicly update or revise any forward-looking
statements, whether as a result of new information or future
events.
Accelr8 (AMEX:AXK)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Accelr8 (AMEX:AXK)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024
Real-Time news about Accelerate Diagnostics, Inc. (American Stock Exchange): 0 recent articles
Plus d'articles sur Accelr8 Technology Corporation